Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York. more
Time Frame | EYEN | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.55% | -0.94% | -2.6% |
1-Month Return | -4.95% | -5.08% | -1.08% |
3-Month Return | -81.54% | -10.62% | 3.45% |
6-Month Return | -87.29% | -6.18% | 8.57% |
1-Year Return | -95.73% | 1.98% | 24.3% |
3-Year Return | -97.95% | -0.93% | 25.58% |
5-Year Return | -97.75% | 33.84% | 84.07% |
10-Year Return | -99.15% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 2.00M | 14.00M | 10.00M | 3.79K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":14.29,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":71.43,"profit":true},{"date":"2023-12-31","value":0.03,"profit":true}] |
Cost of Revenue | 15.34K | 800.00K | 1.60M | 307.43K | 3.79K | [{"date":"2019-12-31","value":0.96,"profit":true},{"date":"2020-12-31","value":50,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":19.21,"profit":true},{"date":"2023-12-31","value":0.24,"profit":true}] |
Gross Profit | (15.34K) | 1.20M | 12.40M | (307.43K) | (783.21K) | [{"date":"2019-12-31","value":-0.12,"profit":false},{"date":"2020-12-31","value":9.68,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2.48,"profit":false},{"date":"2023-12-31","value":-6.32,"profit":false}] |
Gross Margin | - | 60.00% | 88.57% | (3.07%) | (20681.49%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":67.74,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-3.47,"profit":false},{"date":"2023-12-31","value":-23350.07,"profit":false}] |
Operating Expenses | 21.31M | 20.98M | 25.30M | 26.91M | 25.41M | [{"date":"2019-12-31","value":79.18,"profit":true},{"date":"2020-12-31","value":77.96,"profit":true},{"date":"2021-12-31","value":94.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.41,"profit":true}] |
Operating Income | (21.31M) | (19.78M) | (12.90M) | (26.91M) | (25.41M) | [{"date":"2019-12-31","value":-2130854400,"profit":false},{"date":"2020-12-31","value":-1977922500,"profit":false},{"date":"2021-12-31","value":-1290368300,"profit":false},{"date":"2022-12-31","value":-2691151500,"profit":false},{"date":"2023-12-31","value":-2540644600,"profit":false}] |
Total Non-Operating Income/Expense | 303.57K | 28.72K | (259.94K) | (2.40M) | (3.90M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":9.46,"profit":true},{"date":"2021-12-31","value":-85.63,"profit":false},{"date":"2022-12-31","value":-789.39,"profit":false},{"date":"2023-12-31","value":-1285.55,"profit":false}] |
Pre-Tax Income | (21.16M) | (19.77M) | (12.78M) | (28.01M) | (27.26M) | [{"date":"2019-12-31","value":-2115675800,"profit":false},{"date":"2020-12-31","value":-1976986700,"profit":false},{"date":"2021-12-31","value":-1277838700,"profit":false},{"date":"2022-12-31","value":-2801115700,"profit":false},{"date":"2023-12-31","value":-2726109600,"profit":false}] |
Income Taxes | (167.13K) | (78.37K) | 213.38K | (280.42K) | 2.00 | [{"date":"2019-12-31","value":-78.33,"profit":false},{"date":"2020-12-31","value":-36.73,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-131.42,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (20.99M) | (19.69M) | (12.99M) | (27.73M) | (27.26M) | [{"date":"2019-12-31","value":-2098962900,"profit":false},{"date":"2020-12-31","value":-1969149400,"profit":false},{"date":"2021-12-31","value":-1299176300,"profit":false},{"date":"2022-12-31","value":-2773074100,"profit":false},{"date":"2023-12-31","value":-2726109800,"profit":false}] |
Income From Continuous Operations | (21.16M) | (19.77M) | (12.78M) | (28.01M) | (25.42M) | [{"date":"2019-12-31","value":-2115675800,"profit":false},{"date":"2020-12-31","value":-1976986700,"profit":false},{"date":"2021-12-31","value":-1277838700,"profit":false},{"date":"2022-12-31","value":-2801115700,"profit":false},{"date":"2023-12-31","value":-2541735500,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (20.99M) | (19.69M) | (12.99M) | (27.73M) | (27.26M) | [{"date":"2019-12-31","value":-2098962900,"profit":false},{"date":"2020-12-31","value":-1969149400,"profit":false},{"date":"2021-12-31","value":-1299176300,"profit":false},{"date":"2022-12-31","value":-2773074100,"profit":false},{"date":"2023-12-31","value":-2726109600,"profit":false}] |
EPS (Diluted) | (1.54) | (0.96) | (0.51) | (0.84) | (0.67) | [{"date":"2019-12-31","value":-154,"profit":false},{"date":"2020-12-31","value":-96,"profit":false},{"date":"2021-12-31","value":-51,"profit":false},{"date":"2022-12-31","value":-84,"profit":false},{"date":"2023-12-31","value":-67,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
EYEN | |
---|---|
Cash Ratio | 0.46 |
Current Ratio | 0.74 |
Quick Ratio | 0.55 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
EYEN | |
---|---|
ROA (LTM) | -92.94% |
ROE (LTM) | -914.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
EYEN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.84 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.16 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
EYEN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 302.64 |
P/B | 2.61 |
Price/FCF | NM |
EV/R | 487.83 |
EV/Ebitda | NM |
Eyenovia Inc (EYEN) share price today is $0.0845
Yes, Indians can buy shares of Eyenovia Inc (EYEN) on Vested. To buy Eyenovia Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EYEN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Eyenovia Inc (EYEN) via the Vested app. You can start investing in Eyenovia Inc (EYEN) with a minimum investment of $1.
You can invest in shares of Eyenovia Inc (EYEN) via Vested in three simple steps:
The 52-week high price of Eyenovia Inc (EYEN) is $2.57. The 52-week low price of Eyenovia Inc (EYEN) is $0.08.
The price-to-earnings (P/E) ratio of Eyenovia Inc (EYEN) is
The price-to-book (P/B) ratio of Eyenovia Inc (EYEN) is 2.61
The dividend yield of Eyenovia Inc (EYEN) is 0.00%
The market capitalization of Eyenovia Inc (EYEN) is $9.50M
The stock symbol (or ticker) of Eyenovia Inc is EYEN